This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neutze, J. M. Articles by Barratt-Boyes, B. G. Search for Related Content PubMed PubMed Citation Articles by Neutze, J. M. Articles by Barratt-Boyes, B. G.

Circulation, Vol 55, 238-241, Copyright © 1977 by American Heart Association

ARTICLES

Palliation of cyanotic congenital heart disease in infancy with E-type prostaglandins

JM Neutze, MB Starling, RB Elliott and BG Barratt-Boyes

Prostaglandin-E (PGE) infusions have been used in an attempt to increase ductal patency in 11 infants aged one to 99 days with cyanotic heart disease. PGE1 was used in nine infants and PGE2 in two. Five patients had pulmonary atresia, four extreme pulmonary stenosis, one Ebstein's anomaly and one simple transposition of the great arteries. All but the oldest infant showed a satisfactory increase in oxygen saturation (average 36%) attributed to dilatation of the ductus. The failure in one infant may have been due largely to hypoplasia of the left pulmonary artery. The only important side effect was apnea in one infant receiving PGE2. The efficacy of this form of treatment is confirmed in infants dependent on ductal patency for survival. PGE is an important asset in saving the lives of neonates requiring an aorticopulmonary shunt operation. The recommended starting dose is 0.1 mug/kg/min of PGE1 given by constant infusion.

This article has been cited by other articles:

				H. Hasegawa, Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Sunazuka, T. Izuhara, K. Sugahara, K. Tsuruda, M. Masuda, et al. A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-{Delta}12, 14 prostaglandin J2 production Blood, September 1, 2007; 110(5): 1664 - 1674. [Abstract] [Full Text] [PDF]

				M. Artman, R. J. Boucek Jr, J. Hammon, and T. P. Graham Jr Emergency Palliation of Critical Valvular Aortic Stenosis: A New Application of Prostaglandin E1 Arch Pediatr Adolesc Med, April 1, 1983; 137(4): 339 - 340. [Abstract] [PDF]